 Melanoma, Experimental
"Melanoma, Experimental" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.
| Descriptor ID |
D008546
|
| MeSH Number(s) |
C04.557.465.625.650.510.525 C04.557.580.625.650.510.525 C04.557.665.510.525 C04.619.600 E05.598.500.496.937
|
| Concept/Terms |
Melanoma, Experimental- Melanoma, Experimental
- Melanomas, Experimental
- Experimental Melanoma
- Experimental Melanomas
Melanoma, B16- Melanoma, B16
- B16 Melanomas
- Melanomas, B16
- B16 Melanoma
|
Below are MeSH descriptors whose meaning is more general than "Melanoma, Experimental".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neuroendocrine Tumors [C04.557.465.625.650]
- Melanoma [C04.557.465.625.650.510]
- Melanoma, Experimental [C04.557.465.625.650.510.525]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neuroendocrine Tumors [C04.557.580.625.650]
- Melanoma [C04.557.580.625.650.510]
- Melanoma, Experimental [C04.557.580.625.650.510.525]
- Nevi and Melanomas [C04.557.665]
- Melanoma [C04.557.665.510]
- Melanoma, Experimental [C04.557.665.510.525]
- Neoplasms, Experimental [C04.619]
- Melanoma, Experimental [C04.619.600]
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
- Investigative Techniques [E05]
- Models, Animal [E05.598]
- Disease Models, Animal [E05.598.500]
- Neoplasms, Experimental [E05.598.500.496]
- Melanoma, Experimental [E05.598.500.496.937]
Below are MeSH descriptors whose meaning is more specific than "Melanoma, Experimental".
This graph shows the total number of publications written about "Melanoma, Experimental" by people in this website by year, and whether "Melanoma, Experimental" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 2 | 0 | 2 | | 1998 | 5 | 1 | 6 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 3 | 3 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 2 | 3 | | 2004 | 0 | 1 | 1 | | 2005 | 2 | 1 | 3 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 2 | 3 | | 2011 | 3 | 1 | 4 | | 2012 | 0 | 1 | 1 | | 2013 | 4 | 0 | 4 | | 2014 | 2 | 0 | 2 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 1 | 3 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 1 | 2 | | 2019 | 4 | 0 | 4 | | 2020 | 0 | 2 | 2 | | 2021 | 1 | 1 | 2 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Melanoma, Experimental" by people in Profiles.
-
Qiao Z, Xu J, Gonzalez R, Miao Y. Effects of Polyethylene Glycol and 8-Aminooctanoic Acid Linkers on Melanoma Uptake of [99mTc]Tc-Tricarbonyl-NOTA-Conjugated Lactam-Cyclized a-MSH Peptides. Bioconjug Chem. 2023 05 17; 34(5):934-940.
-
Qiao Z, Xu J, Gonzalez R, Miao Y. Novel 64Cu-Labeled NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Enhanced Tumor to Kidney Uptake Ratios. Mol Pharm. 2022 07 04; 19(7):2535-2541.
-
Qiao Z, Xu J, Gonzalez R, Miao Y. Novel Al18F-NOTA-Conjugated Lactam-Cyclized a-Melanocyte-Stimulating Hormone Peptides with Enhanced Melanoma Uptake. Bioconjug Chem. 2022 05 18; 33(5):982-990.
-
Torphy RJ, Sun Y, Lin R, Caffrey-Carr A, Fujiwara Y, Ho F, Miller EN, McCarter MD, Lyons TR, Schulick RD, Kedl RM, Zhu Y. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models. Nat Commun. 2022 01 10; 13(1):97.
-
Xu J, Gallazzi F, Fisher DR, Gonzalez R, Miao Y. The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of 67Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. Cancer Biother Radiopharm. 2022 Feb; 37(1):47-55.
-
Tewari A, Prabagar MG, Gibbings SL, Rawat K, Jakubzick CV. LN Monocytes Limit DC-Poly I:C Induced Cytotoxic T Cell Response via IL-10 and Induction of Suppressor CD4 T Cells. Front Immunol. 2021; 12:763379.
-
Tengesdal IW, Dinarello A, Powers NE, Burchill MA, Joosten LAB, Marchetti C, Dinarello CA. Tumor NLRP3-Derived IL-1? Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. Front Immunol. 2021; 12:661323.
-
Tengesdal IW, Menon DR, Osborne DG, Neff CP, Powers NE, Gamboni F, Mauro AG, D'Alessandro A, Stefanoni D, Henen MA, Mills TS, De Graaf DM, Azam T, Vogeli B, Palmer BE, Pietras EM, DeGregori J, Tan AC, Joosten LAB, Fujita M, Dinarello CA, Marchetti C. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc Natl Acad Sci U S A. 2021 03 09; 118(10).
-
Tu MM, Abdel-Hafiz HA, Jones RT, Jean A, Hoff KJ, Duex JE, Chauca-Diaz A, Costello JC, Dancik GM, Tamburini BAJ, Czerniak B, Kaye J, Theodorescu D. Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Commun Biol. 2020 11 27; 3(1):720.
-
Xu J, Qiao Z, Gonzalez R, Miao Y. Facile preparation of a novel Ga-67-labeled NODAGA-conjugated lactam-cyclized alpha-MSH peptide at room temperature for melanoma targeting. Bioorg Med Chem Lett. 2020 12 15; 30(24):127627.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|